The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?
The efficiency of cardiovascular risk assessment: do the right patients get statin treatment?
复制标题
DOI：
10.1136/heartjnl-2013-303698
复制
发表时间：
2013-11-01
期刊：
影响因子：
5.7
通讯作者：
Gulliford, Martin
中科院分区：
文献类型：
--
作者：
van Staa, Tjeerd-Pieter;Smeeth, Liam;Gulliford, Martin
目的评价他汀类药物在心血管疾病（CVD）高危人群一级预防中的靶向作用。74年。在临床实践研究数据链中设置英国初级保健记录。患者380万普通人群患者和300 914名他汀类药物使用者。他汀类药物干预处方。主要结局指标他汀类药物根据CVD风险开处方; 5年CVD风险;结果随着时间的推移，他汀类药物处方大幅增加，高10年心血管疾病风险（20%）的患者：7.0%的人在2007年之前接受他汀类药物治疗，2007年以后为30.4%。为低风险患者开处方（
Objective To evaluate targeting of statin prescribing for primary prevention to those with high cardiovascular disease (CVD) risk.Design Two cohort studies including the general population and initiators of statins aged 35-74 years.Setting UK primary care records in the Clinical Practice Research Datalink.Patients 3.8 million general population patients and 300 914 statin users.Intervention Statin prescribing.Main outcome measures Statin prescribing by CVD risk; observed 5-year CVD risks; variability between practices.Results Statin prescribing increased substantially over time to patients with high 10-year CVD risk (20%): 7.0% of these received a statin prior to 2007, and 30.4% in 2007 onwards. Prescribing to patients with low risk (